retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Retatrutide Who Makes Retatrutide? Company Behind

According to reported trial data, adults taking the 12 mg dose lost an average of 70.3 pounds, equal to about 28.3% of body weight, over 80 weeks

Lancet 2025

We replaced the tryptophan cage (Trp-cage) at the C terminus of exendin-4 (21, 43-45) despite its presence in Tirzepatide (Kegg Drug D11360) and stapled GLP-1R dual agonist O14(25) as previous studies reported the redundancy of the motif for the preservation of high binding affinity for GLP-1R (45)

However, their benefits are mild compared to the GLP-1 agonists (McIntyre RS et al, Am J Psychiatry 2024;181:2638)

One study reported that 12 weeks of endurance training significantly improved lower limb and whole-body bone mineral content, as well as whole-body and pelvic BMD in obese participants